{"id":63147,"date":"2026-05-22T07:04:53","date_gmt":"2026-05-22T05:04:53","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/"},"modified":"2026-05-22T07:04:53","modified_gmt":"2026-05-22T05:04:53","slug":"outcome-of-innate-pharmas-2026-annual-general-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/","title":{"rendered":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting"},"content":{"rendered":"
\n

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News:<\/p>\n

<\/a>
<\/a><\/p>\n

\nInnate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate<\/b>\u201d or the \u201cCompany<\/b>\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 21, 2026, in Marseille. All resolutions were voted.<\/p>\n

\nA total of 94 votes were cast out of a total of 34,872,293 shares giving right to 34,921,313 voting rights, representing a quorum of 37,136%.<\/p>\n

\nThe resolutions, the results of the votes and other documents relating to the AGM along with the AGM recording will be available in the Annual General Meeting 2026<\/a> section of the Company\u2019s website.<\/p>\n

\nAbout Innate Pharma<\/b><\/p>\n

\nInnate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Leveraging its expertise on antibody-engineering and innovative target identification, Innate Pharma is developing innovative and differentiated next-generation antibody therapeutics.<\/p>\n

\nInnate Pharma is advancing a portfolio of differentiated potential first and\/or best-in-class assets, focused on areas of high unmet medical need, including IPH4502, a differentiated Nectin-4 ADC developed in solid tumors, lacutamab, an anti-KIR3DL2 antibody developed in cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.<\/p>\n

\nInnate Pharma has established collaborations with leading biopharmaceutical companies, including Sanofi and AstraZeneca, as well as renowned academic and research institutions, to advance innovation in immuno-oncology.<\/p>\n

\nHeadquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.<\/p>\n

\nLearn more about Innate Pharma at www.innate-pharma.com<\/a>. Follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n

\nInformation about Innate Pharma shares<\/b><\/p>\n\n\n
\n

\nISIN code<\/b>
Ticker code<\/b>
LEI<\/b><\/p>\n<\/td>\n

\n

\nFR0010331421<\/p>\n

\nEuronext: IPH Nasdaq: IPHA<\/p>\n

\n9695002Y8420ZB8HJE29<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nDisclaimer on forward-looking information and risk factors<\/b><\/p>\n

\nFor a discussion of risks and uncertainties, please refer to the Risk Factors (\u201cFacteurs de Risque”) section of the Universal Registration Document filed with the French Financial Markets Authority (\u201cAMF\u201d), which is available on the AMF website (http:\/\/www.amf-france.org<\/a>) or on Innate Pharma\u2019s website (www.innate-pharma.com<\/a>), and public filings and reports filed with the U.S. Securities and Exchange Commission (\u201cSEC\u201d), including the Company\u2019s Annual Report on Form 20-F for the year ended December 31, 2025, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company\u2019s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.<\/p>\n

\nThis press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.<\/p>\n

Contacts<\/b> <\/p>\n

\nFor additional information, please contact:<\/b><\/p>\n

\nI<\/span><\/b>nvestors & Media Relations<\/b><\/span>
Innate Pharma<\/b>
St\u00e9phanie Cornen
\n
stephanie.cornen@innate-pharma.fr<\/a><\/p>\n

\nInvestor Relations<\/b>
investors@innate-pharma.fr<\/a><\/p>\n

\nMedia<\/b>
communication@innate-pharma.fr<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a total of 34,872,293 … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-63147","format-standard","category-industry"],"yoast_head":"\nOutcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a total of 34,872,293 ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-22T05:04:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting\",\"datePublished\":\"2026-05-22T05:04:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/\"},\"wordCount\":496,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260521175904\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/\",\"name\":\"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260521175904\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"datePublished\":\"2026-05-22T05:04:53+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260521175904\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260521175904\\\/en\\\/1245155\\\/22\\\/INNATEvertnoirDS.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/outcome-of-innate-pharmas-2026-annual-general-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend","og_description":"MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (\u201cInnate\u201d or the \u201cCompany\u201d) announced the voting results of its shareholders at the Annual General Meeting (\u201cAGM\u201d), which took place on May 21, 2026, in Marseille. All resolutions were voted. A total of 94 votes were cast out of a total of 34,872,293 ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2026-05-22T05:04:53+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting","datePublished":"2026-05-22T05:04:53+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/"},"wordCount":496,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/","url":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/","name":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg","datePublished":"2026-05-22T05:04:53+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260521175904\/en\/1245155\/22\/INNATEvertnoirDS.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/outcome-of-innate-pharmas-2026-annual-general-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Outcome of Innate Pharma\u2019s 2026 Annual General Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63147","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=63147"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/63147\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=63147"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=63147"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=63147"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}